Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saußele, Martin C. Müller, Martin Bentz et al.|Blood|2015Cited by 200
Community-driven development of a modified progression-free survival ratio for precision oncologyAndreas Möck, Anna Lena Illert, Christoph E. Heilig et al.|ESMO Open|2019Cited by 44
Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trialHermann Einsele, Stefan Knop, Monika Engelhardt et al.|British Journal of Haematology|2017Cited by 30
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Michael Lauseker, Elza Lomaia et al.|Leukemia|2024Cited by 25
Preinfection laboratory parameters may predict COVID‐19 severity in tumor patientsAlexander Kiani, Ralph Naumann, Romina Roesch et al.|Cancer Medicine|2021Cited by 6